文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

非酒精性脂肪性肝病中心血管疾病的病理生理机制

Pathophysiological mechanisms of cardiovascular disorders in non-alcoholic fatty liver disease.

作者信息

Garbuzenko Dmitry Victorovich

机构信息

Department of Faculty Surgery, South Ural State Medical University, Chelyabinsk, Russia.

出版信息

Gastroenterol Hepatol Bed Bench. 2022 Summer;15(3):194-203. doi: 10.22037/ghfbb.v15i3.2549.


DOI:10.22037/ghfbb.v15i3.2549
PMID:36311966
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9589137/
Abstract

Non-alcoholic fatty liver disease is one of the main liver diseases worldwide. The most common cause of death in patients with non-alcoholic fatty liver disease is cardiovascular disease. The relationship between these two conditions has been well established. Indeed, identical reasons may contribute to the development of cardiovascular disease and non-alcoholic fatty liver disease with lifestyle factors such as smoking, sedentariness, poor nutritional habits, and physical inactivity being major aspects. This review focuses on potential pathophysiological mechanisms of cardiovascular disorders in non-alcoholic fatty liver. PubMed, EMBASE, Orphanet, MIDLINE, Google Scholar, and Cochrane Library were searched for articles published between 2006 and 2022. Relevant articles were selected using the following terms: "Non-alcoholic fatty liver disease," "Сardiovascular diseases," "Pathophysiological mechanisms." The reference lists of all identified articles were searched for other relevant publications as well. The pathophysiological mechanisms of cardiovascular disorders in non-alcoholic fatty liver remain largely speculative and may include systemic low-grade inflammation, atherogenic dyslipidemia, abnormal glucose metabolism and hepatic insulin resistance, endothelial dysfunction, gut dysbiosis, as well as the associated cardiac remodeling, which are influenced by interindividual genetic and epigenetic variations. It is clear that the identification of pathophysiological mechanisms underlying cardiovascular disorders in non-alcoholic fatty liver disease will make the selection of therapeutic measures more optimal and effective.

摘要

非酒精性脂肪性肝病是全球主要的肝脏疾病之一。非酒精性脂肪性肝病患者最常见的死因是心血管疾病。这两种疾病之间的关系已得到充分证实。事实上,相同的原因可能导致心血管疾病和非酒精性脂肪性肝病的发生,吸烟、久坐不动、不良饮食习惯和缺乏体育锻炼等生活方式因素是主要方面。本综述重点关注非酒精性脂肪性肝病中心血管疾病潜在的病理生理机制。通过检索PubMed、EMBASE、Orphanet、MIDLINE、谷歌学术和Cochrane图书馆,查找2006年至2022年期间发表的文章。使用以下术语选择相关文章:“非酒精性脂肪性肝病”、“心血管疾病”、“病理生理机制”。还对所有已识别文章的参考文献列表进行检索,以查找其他相关出版物。非酒精性脂肪性肝病中心血管疾病的病理生理机制在很大程度上仍属推测,可能包括全身低度炎症、致动脉粥样硬化血脂异常、异常葡萄糖代谢和肝脏胰岛素抵抗、内皮功能障碍、肠道菌群失调以及相关的心脏重塑,这些都受到个体间遗传和表观遗传变异的影响。显然,确定非酒精性脂肪性肝病中心血管疾病的病理生理机制将使治疗措施的选择更加优化和有效。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3eb8/9589137/9c7db35a0f90/GHFBB-15-194-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3eb8/9589137/9c7db35a0f90/GHFBB-15-194-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3eb8/9589137/9c7db35a0f90/GHFBB-15-194-g001.jpg

相似文献

[1]
Pathophysiological mechanisms of cardiovascular disorders in non-alcoholic fatty liver disease.

Gastroenterol Hepatol Bed Bench. 2022

[2]
Nonalcoholic Fatty liver disease/non-alcoholic steatohepatitis in childhood: endocrine-metabolic "mal-programming".

Hepat Mon. 2014-5-1

[3]
Mechanisms of adaptation of the hepatic vasculature to the deteriorating conditions of blood circulation in liver cirrhosis.

World J Hepatol. 2016-6-8

[4]
Cardiovascular Risk in Fatty Liver Disease: The Liver-Heart Axis-Literature Review.

Front Med (Lausanne). 2019-9-13

[5]
NAFLD and Cardiovascular Diseases: Epidemiological, Mechanistic and Therapeutic Considerations.

J Clin Med. 2021-1-26

[6]
Metabolic dysfunction-associated fatty liver disease (MAFLD) as a more accurate name for NAFLD - common aspects of pathogenesis.

Cas Lek Cesk. 2022

[7]
The potential pathophysiological role of altered lipid metabolism and electronegative low-density lipoprotein (LDL) in non-alcoholic fatty liver disease and cardiovascular diseases.

Clin Chim Acta. 2021-12

[8]
Non-alcoholic fatty liver disease and cardiovascular disease: epidemiological, clinical and pathophysiological evidences.

Intern Emerg Med. 2012-10

[9]
Pathophysiological Molecular Mechanisms of Obesity: A Link between MAFLD and NASH with Cardiovascular Diseases.

Int J Mol Sci. 2021-10-27

[10]
Modern approach to the clinical management of non-alcoholic fatty liver disease.

World J Gastroenterol. 2014-7-14

引用本文的文献

[1]
Cardiac Remodeling and Arrhythmic Burden in Pre-Transplant Cirrhotic Patients: Pathophysiological Mechanisms and Management Strategies.

Biomedicines. 2025-3-28

[2]
Metabolic Dysfunction-Associated Steatotic Liver Disease: Pathogenetic Links to Cardiovascular Risk.

Biomolecules. 2025-1-22

[3]
Non-Alcoholic Fatty Liver Disease and Coronary Artery Disease: A Bidirectional Association Based on Endothelial Dysfunction.

Int J Mol Sci. 2024-10-1

[4]
Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases.

Front Cell Dev Biol. 2024-7-16

[5]
Mortality, Hepatic Decompensation, and Cardiovascular- and Renal-Related Outcomes in Lean Versus Non-lean Patients Hospitalized With Metabolic Dysfunction-Associated Steatohepatitis (MASH).

Cureus. 2024-5-24

[6]
System failure: Systemic inflammation following spinal cord injury.

Eur J Immunol. 2024-1

[7]
Non-alcoholic fatty liver disease (NAFLD) is associated with an increased incidence of chronic kidney disease (CKD).

Eur J Med Res. 2023-4-17

[8]
Polyunsaturated and Saturated Oxylipin Plasma Levels Allow Monitoring the Non-Alcoholic Fatty Liver Disease Progression to Severe Stages.

Antioxidants (Basel). 2023-3-13

本文引用的文献

[1]
Overlooked subclinical portal hypertension in non-cirrhotic NAFLD: Is it real and how to measure it?

J Hepatol. 2022-2

[2]
Review article: non-alcoholic fatty liver disease and cardiovascular diseases: associations and treatment considerations.

Aliment Pharmacol Ther. 2021-10

[3]
Non-alcoholic fatty liver disease-related risk of cardiovascular disease and other cardiac complications.

Diabetes Obes Metab. 2022-2

[4]
Nonalcoholic Fatty Liver Disease and Cardiac Remodeling Risk: Pathophysiological Mechanisms and Clinical Implications.

Hepatology. 2021-11

[5]
Mitochondrial Lipid Homeostasis at the Crossroads of Liver and Heart Diseases.

Int J Mol Sci. 2021-6-28

[6]
Non-Alcoholic Fatty Liver Disease and Cardiovascular Comorbidities: Pathophysiological Links, Diagnosis, and Therapeutic Management.

Diagnostics (Basel). 2021-4-12

[7]
Cardiac Morphology, Function, and Hemodynamics in Patients With Morbid Obesity and Nonalcoholic Steatohepatitis.

J Am Heart Assoc. 2021-4-20

[8]
Cardiovascular Disease in Nonalcoholic Steatohepatitis: Screening and Management.

Curr Hepatol Rep. 2020-9

[9]
NAFLD and Cardiovascular Diseases: Epidemiological, Mechanistic and Therapeutic Considerations.

J Clin Med. 2021-1-26

[10]
NAFLD and cardiovascular diseases: a clinical review.

Clin Res Cardiol. 2021-7

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索